While $NVIDIA(NVDA)$ gets all the headlines for AI chips, a massive shift is happening behind the scenes. Big tech companies (hyperscalers) are trying to cut costs. Instead of buying expensive, one-size-fits-all GPUs, they are turning to Custom ASICs—tailor-made chips built for specific AI tasks. Two players are leading this charge: $Broadcom(AVGO)$ and $Marvell Technology(MRVL)$ . But they offer two very different ways to play the AI boom. Get your free vouchers from linktr.ee/ChillOnSunday 🔵 Broadcom (AVGO): The Steady Compounder Broadcom dominates the AI custom chip market (holding roughly 60% to 80%) with giants like Google and Meta. It isn't just a chipmaker

Broadcom delivered strong Q3 numbers and mapped out massive multi-gigawatt custom AI chip orders across Anthropic, OpenAI, and Meta through 2028. However, an in-line near-term forecast triggered immediate post-earnings profit-taking, knocking shares down toward key chart support around $360. For options traders, this pullback creates defined-risk opportunities to monetize volatility rather than chasing momentum. Executive summary Achieved record Q3 revenue of $29.6 billion, up 86% year-over-year, driven by strong demand for AI accelerators and networking. Q3 GAAP operating income reached $16.0 billion; non-GAAP operating income was $20.1 billion, up 92% year-over-year. Q3 GAAP diluted EPS was $2.68; non-GAAP diluted EPS was $3.32, up 96% year-over-year. Free cash flow for Q3 was $13.7 bill

$AbbVie(ABBV)$ is a leading global biopharmaceutical company based in the United States. Ranked among the largest in the industry, it develops treatments across key areas including immunology, cancer, neurology, and aesthetics. Its major products include blockbuster medicines like Humira, Skyrizi, and Rinvoq for autoimmune conditions, cancer therapies like Imbruvica and Venclexta, mental health medication Vraylar, and Botox. The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.' In a long-term uptrend, but it is currently hitting a strong price ceiling at $260–$262. Momentum is slowing down, which suggests sellers are stepping in and could cause

With $S&P 500(.SPX)$ hitting fresh ALL TIME HIGH, staying exposed overnight can magnify emotional worry and gap risk. Day trading options allows traders to participate in strong intraday momentum while keeping overnight downside risk strictly capped.[Cool] WHY I DAY TRADE OPTIONS ( $SPDR S&P 500 ETF Trust(SPY)$ ,0DTE) Holding equity positions overnight often leaves investors vulnerable to market-moving pre-market headlines. Overnight Peace of Mind: Holding swing positions can cause worry and fear to expand as headlines break overnight[Drowsy]. Closing intraday setups means going to bed flat with zero overnight risk. Controlled Downside Risk: By using a defined-risk option strategy (a setup where th

Citadel stepped in to buy heavily discounted tech assets from Situational Awareness after high leverage triggered severe margin calls, halting a forced liquidation cascade and lifting the market overhang. Market Impact: Net positive for short-term relief, but neutral for medium-term fundamentals. Liquidation Relief: Absorbing the distressed book at a 10% discount ended forced market dumping and stabilized prices across AI benchmarks like $Invesco QQQ(QQQ)$ . Institutional Floor: Smart money stepping in establishes a psychological floor, signaling that institutional investors view risk-adjusted valuations as attractive near key support levels. IF YOU ALREADY OWN THE SHARES Action: Consider selling a covered call (selling the right for someone else t

AstraZeneca is in preliminary talks to acquire $Bristol-Myers Squibb(BMY)$ in a potential $400 billion mega-merger. While unconfirmed talks spark immediate speculative upside for BMY, regulatory scrutiny over overlapping oncology pipelines means traders should expect elevated volatility rather than a guaranteed buyout. Thank you for your LIKE and FOLLOW. I heard you, TIGERSSS. Option Comm Free Vouchers are available for you. Contact me before it ends. IF YOU ALREADY OWN THE SHARES If you hold 100 or more shares of BMY, you can consider selling covered calls (selling the right for someone else to buy your shares at a specified target price to collect upfront income) out-of-the-money. With BMY trading near $65.31 and underlying implied volatility (IV

$Palantir Technologies Inc.(PLTR)$ fell 6.08% to $123.53 as short-term traders took profits and de-risked ahead of its August 3 post-market earnings report. This pullback creates a negative short-term impact due to broader market anxieties around high software valuations and AI capital expenditure returns, making price swings unpredictable. However, the medium-term core foundation remains intact—driven by solid government and commercial AI contracts—meaning Palantir will need both a revenue beat and strong future guidance to launch a major rally. High options implied volatility (IV, a metric reflecting expected price swings) is now pricing in significant earnings uncertainty. IF YOU ALREADY OWN THE SHARES Action: Consider selling a covered call (s